Morphosys AG
41 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
Recorded under 2 name spellings.
8
Ending by 2030
Dec 2026
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 2 fees due Dec 4 to 23, 2026 · next Dec 4
- 1 fee due Mar 15, 2027The maintenance fee for Screening strategies for the identification of binders (US 9,133,500) comes due Mar 15, 2027. Unpaid by Sep 15, 2027, it lapses early.
- 2 fees due Jul 14 to 26, 2027 · next Jul 14
- 1 fee due Sep 22, 2027The maintenance fee for Combinations and uses thereof (US 9,289,490) comes due Sep 22, 2027. Unpaid by Mar 22, 2028, it lapses early.
- 1 fee due Oct 28, 2027The maintenance fee for Antibodies for IL-17C (US 10,633,439) comes due Oct 28, 2027. Unpaid by Apr 28, 2028, it lapses early.
- 1 fee due Nov 12, 2027The maintenance fee for Collection and methods for its use (US 10,647,757) comes due Nov 12, 2027. Unpaid by May 12, 2028, it lapses early.
Recent changes
- 1 of the patents on this record was granted since Aug 16, 2026
- 4 terms have ended since Aug 16, 2026
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 9,193,799 | Fully Human Therapeutic Antibodies Specific for Human CD38 In force · High confidence | In force | High confidence | |
| US 11,939,395 | GENERATION AND PROFILING OF FULLY HUMAN HuCAL GOLD-DERIVED THERAPEUTIC ANTIBODIES SPECIFIC FOR HUMAN CD38 In force · High confidence | In force | High confidence | |
| US 11,059,902 | GENERATION AND PROFILING OF FULLY HUMAN HuCAL GOLD-DERIVED THERAPEUTIC ANTIBODIES SPECIFIC FOR HUMAN CD38 In force · High confidence | In force | High confidence | |
| US 8,088,896 | Generation and Profiling of Fully Human Gold-Derived Therapeutic Antibodies Specific for Human CD38 In force · High confidence | In force | High confidence | |
| US 8,273,688 | Collection of HCDR3 regions and uses therefor In force · From the USPTO record | In force | From the USPTO record | |
| US 9,062,097 | Methods for the formation of disulphide bonds In force · From the USPTO record | In force | From the USPTO record | |
| US 8,685,896 | Collection and methods for its use In force · From the USPTO record | In force | From the USPTO record | |
| US 9,133,500 | Screening strategies for the identification of binders In force · From the USPTO record | In force | From the USPTO record | |
| US 10,647,757 | Collection and methods for its use In force · From the USPTO record | In force | From the USPTO record | |
| US 8,337,850 | 4-1BB Binding Molecules In force · High confidence | In force | High confidence |
Also on record, not counted in the 38: 41 patents in force now held by others · 57 lapsed for an unpaid fee · 31 ended at full term. List them
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
18 pending · 25 abandoned · 22 no status recorded